These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12053490)

  • 1. [Diurnal rhythm of endogenous somatostatin in patients with carcinoid].
    Kinová S; Kovácová E; Kratochvíĺová E; Ondrejka P; Duris I
    Cesk Fysiol; 2002 May; 51(2):69-74. PubMed ID: 12053490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoid tumors--somatostatine in the diagnosis and therapy.
    Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
    Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored intermittent therapy of carcinoid.
    Kinová S; Duris I; Kratochvíl'ová E; Kovácová E; Koren M
    Hepatogastroenterology; 2007 Sep; 54(78):1716-9. PubMed ID: 18019702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian rhythmicity of plasma somatostatin, gastrin and cortisol in colon cancer patients.
    Payer J; Huorka M; Duris I; Ondrejka P; Kratochvílova H; Ilkova M; Holéczy P
    Hepatogastroenterology; 1997; 44(13):72-7. PubMed ID: 9058123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
    Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
    N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
    Rohaizak M; Farndon JR
    ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
    Tomassetti P; Migliori M; Gullo L
    Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
    Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
    J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
    [No Abstract]   [Full Text] [Related]  

  • 11. Metastatic carcinoid tumour of the heart.
    Debouverie O; Vaquette B; Hervochon JM
    Arch Cardiovasc Dis; 2010; 103(8-9):491-2. PubMed ID: 21074130
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatostatin and large bowel polyps.
    Payer J; Huorka M; Duris I; Mikulecky M; Kratochvilovà H; Ondrejka P
    Hepatogastroenterology; 1995; 42(6):775-7. PubMed ID: 8847021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
    Drange MR; Melmed S
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
    Debono M; Hon LQ; Bax N; Blakeborough A; Newell-Price J
    J Clin Endocrinol Metab; 2008 May; 93(5):1860-4. PubMed ID: 18303072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
    Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
    Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
    Igaz P; Rácz K; Tulassay Z
    Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
    Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
    Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian variations of plasma somatostatin levels in healthy subjects.
    Strazzulla G; Guazzelli R; Romano S; Matassi L; Cotrozzi G; Brocchi A
    Chronobiologia; 1990; 17(3):219-25. PubMed ID: 1977563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.